Mylan launches generic Zosyn injection

HERTFORDSHIRE, England and PITTSBURGH — Mylan this week announced the launch of its generic version of Pfizer’s Zosyn (piperacillin and tazobactam) injection. The drug is meant to treat patients with infections caused by susceptible isolates of some bacteria.

Mylan is launching the injection in 3.375-g single-dose vials. According to IMS Health, Zosyn had U.S. sales of about $72.1 million for the 12 months ending June 30. The piperacillin and tazobactam injection joins Mylan’s portfolio of 145 injectables in the U.S.